Staidson (Beijing) Biopharmaceuticals Co Ltd operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Staidson (Beijing) Biopharmaceuticals Co Ltd with three other
companies in this sector in China:
Tianjin Ringpu Bio-Technology Co Ltd
sales of 969.68 million Chinese Renmimbi [US$146.55 million]
of which 63%
was Veterinary Biological Products),
Beijing SL Pharmaceutical Co Ltd
(1.01 billion Chinese Renmimbi [US$152.62 million]
of which 98%
was Pharmaceuticals Industry), and
Jinyu Bio-Technology Co Ltd
(1.52 billion Chinese Renmimbi [US$229.27 million]
of which 95%
Staidson (Beijing) Biopharmaceuticals Co Ltd reported sales of 1.40 billion Chinese Renmimbi (US$212.08 million)
December of 2016.
increase of 12.5%
versus 2015, when the company's sales were 1.25 billion Chinese Renmimbi.
Sales at Staidson (Beijing) Biopharmaceuticals Co Ltd have increased during each of the previous five years
(and since 2011, sales have increased a total of 582%).